Reviewers: Komal Arora, M.D., (see Reviewers page)
Revised: 26 March 2012, last major update March 2012
Copyright: (c) 2003-2012, PathologyOutlines.com, Inc.
● Neuroendocrine (NE) cells found in 80% of normal prostates, 10-33% of adenocarcinomas
● Prostatic NE cells most likely derive from local stem cells and represent terminally differentiated and androgen-insensitive cell populations in benign prostate tissue (Ann Oncol 2001;12:S141)
● Extent of neuroendocrine differentiation may provide prognostic information in tumors with Gleason score 2-6 treated by radical prostatectomy (Hum Pathol 1996;27:683, Urologe A 2004;43:836, Indian J Urol 2010;26:41)
● Pure neuroendocrine carcinomas not associated with elevated PSA
● NE differentiation arises in three different forms: carcinoid, oat cell carcinoma, focally NE-differentiated conventional tumor
● Selective expression of stem cell-associated markers, such as CD44/Oct4A gene, in NE cancerous cells explain their therapy escape together with tumor recurrence and metastasis (G Chir 2010;31:586)
● 55 year old man (Pol J Pathol 2011;62:60)
● 73 year old man (Arch Pathol Lab Med 2000;124:1074)
● May resemble Paneth cells with large, basal, eosinophilic granules
● Also resemble typical or atypical carcinoid
Recurrent neuroendocrine carcinoma
● Chromogranin, PSA, PAP
● Bcl2, ACTH, β-endorphin, calcitonin
End of Prostate > Other carcinomas > Neuroendocrine carcinoma
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.
All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).